Research Overview —
Gentry’s research is primarily aimed at understanding the mechanism underlying Diabetic Peripheral Neuropathy. Methylglyoxal is a noxious byproduct of glycolysis that is elevated in patients with diabetes and drives axon loss. However, the direct mechanism of methylglyoxal-induced axon degeneration is not known but could lead to a potential therapeutic target for diabetic peripheral neuropathy. Joined Dr. Douglas Wright, Department of Anesthesiology, KUMC in the Fall of 2022.
Presentations —
- Totta-Griese G, Enders J, Ryals J, Heslop L, Hauser W, and Wright DE, Methylglyoxal, A Noxious Metabolite, Also Drives Nociceptive Axon Loss in the Skin, European Pain School, Siena, Italy 2024
- Totta-Griese G, Enders J, Ryals J, Heslop L, Hauser W, and Wright DE, The Reactive Dicarbonyl, Methylglyoxal, Drives Intraepidermal Nerve Fiber Loss, Peripheral Nerve Society Conference, June 2024
- Totta-Griese G, Enders J, Ryals J, Heslop L, Hauser W, and Wright DE, Methylglyoxal, A Noxious Metabolite, Drives Nociceptive Axon Loss in the Skin, United States Association for the Study of Pain Conference, April 2024
- Totta-Griese G, Enders J, Ryals J, Heslop L, Hauser W, and Wright DE, Methylglyoxal Drives Epidermal Axon Loss, Student Research Forum, April 2024, Kansas University Medical Center, USA
Awards and Honors —
- Best Poster Presentation in Basic Science, United States Association for the Study of Pain Conference, (April 2024)
- First-Place Presentation, Student Research Forum (March 2024)
- Madison and Lila Self Fellow, University of Kansas, (2023-2027)
- Scholar of the Year, Interdisciplinary Graduate Program of Biomedical Sciences, University of Kansas Medical Center, (2022-2023)